The chemistry-biology-medicine continuum and the drug discovery and development process in academia

Chemistry and Biology

Volumn 21, Issue 9, 2014, Pages 1039-1045

  Nicolaou, K C ^a  

^a RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NATURAL PRODUCT; ANTIBODY CONJUGATE; BIOLOGICAL PRODUCT;

BASIC RESEARCH; BIOLOGY; BIOTECHNOLOGY; CANCER STEM CELL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; INTERDISCIPLINARY RESEARCH; MEDICINAL CHEMISTRY; NEOPLASM; PATENT; RARE DISEASE; REVIEW; SYNTHETIC BIOLOGY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG SCREENING; METABOLISM; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH; SYNTHESIS;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNOCONJUGATES; NEOPLASTIC STEM CELLS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910017812     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.07.020     Document Type: Review

References (47)

1. America's Biopharmaceutical Research Companies. (2013a). Biologics research promises to bolster the future of medicine. http://www.phrma.org/sites/default/files/pdf/biologicsoverview2013.pdf.
2. America's Biopharmaceutical Research Companies. (2013b). Biologics research pushing frontiers of science with more than 900 medicines and vaccines in development. http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf.
3. Armitage, E.G., and Barbas, C. (2014). Metabolomics in cancer biomarker discovery: current trends and future perspectives. J. Pharm. Biomed. Anal. 87, 1-11.
4. Benjamin, D.I., Cravatt, B.F., and Nomura, D.K. (2012). Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 16, 565-577.
5. Carothers, J.M., Goler, J.A., and Keasling, J.D. (2009). Chemical synthesis using synthetic biology. Curr. Opin. Biotechnol. 20, 498-503.
6. Chari, R.V.J., Miller, M.L., and Widdison, W.C. (2014). Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53, 3796-3827.
7. Cong, F., Cheung, A.K., and Huang, S.-M.A. (2012). Chemical genetics-based target identification in drug discovery. Annu. Rev. Pharmacol. Toxicol. 52, 57-78.
8. Dai, H.-X., Stepan, A.F., Plummer, M.S., Zhang, Y.-H., and Yu, J.-Q. (2011). Divergent C-H functionalizations directed by sulfonamide pharmacophores: late-stage diversification as a tool for drug discovery. J. Am. Chem. Soc. 133, 7222-7228.
9. Dosio, F., Stella, B., Cerioni, S., Gastaldi, D., and Arpicco, S. (2014). Advances in anticancer antibody-drug conjugates and immunotoxins. Recent Patents Anticancer. Drug Discov. 9, 35-65.
10. Furman, P.A., Davis, M., Liotta, D.C., Paff, M., Frick, L.W., Nelson, D.J., Dornsife, R.E., Wurster, J.A., Wilson, L.J., Fyfe, J.A., et al. (1992). The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2686-2692.
11. Futamura, Y., Muroi, M., and Osada, H. (2013). Target identification of small molecules based on chemical biology approaches. Mol. Biosyst. 9, 897-914.
12. Gerber, H.-P., Koehn, F.E., and Abraham, R.T. (2013). The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 30, 625-639.
13. Henry, N.L., and Hayes, D.F. (2012). Cancer biomarkers. Mol. Oncol. 6, 140-146.
14. Hoogenboom, H.R. (2005). Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105-1116.
15. Jarvis, L.M. (2013). Orphans find a home. Chem. Eng. News 91, 10-12.
16. 18)F-fluorination to PET radiotracer development: overcoming hurdles to translation. PLoS ONE 8, e59187.
17. Klein, C. (2009). Congenital neutropenia. Hematology Am. Soc. Hematol. Educ. Program 2009, 344-350.
18. Marks, P.A., and Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84-90.
19. Moellering, R.E., and Cravatt, B.F. (2012). How chemoproteomics can enable drug discovery and development. Chem. Biol. 19, 11-22.
20. Newman, D.J., and Cragg, G.M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335.
21. Nicolaou, K.C. (2013). The emergence of the structure of the molecule and the art of its synthesis. Angew. Chem. Int. Ed. Engl. 52, 131-146.
22. Nicolaou, K.C. (2014a). Academic-industrial partnerships in drug discovery and development. Angew. Chem. Int. Ed. Engl. 53, 4730-4731.
23. Nicolaou, K.C. (2014b). Advancing the drug discovery and development process. Angew. Chem. Int. Ed. Engl. 53, 9128-9140.
24. Nicolaou, K.C., and Montagnon, T. (2008). Molecules that Changed the World: a Brief History of the Art and Science of Synthesis and Its Impact on Society. (Weinheim, Germany: Wiley-VCH Publishers).
25. Nicolaou, K.C., Hale, C.R., Nilewski, C., and Ioannidou, H.A. (2012). Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance. Chem. Soc. Rev. 41, 5185-5238.
26. Parmenides Foundation (2014). The Parmenides Eidos(™) Visual Reasoning Language and the Cognitive Excellence Program (CEP). http://www.Parmenides-Foundation.org.
27. Perez, H.L., Cardarelli, P.M., Deshpande, S., Gangwar, S., Schroeder, G.M., Vite, G.D., and Borzilleri, R.M. (2014). Antibody-drug conjugates: current status and future directions. Drug Discov. Today 19, 869-881.
28. Prinz, F., Schlange, T., and Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712.
29. Saag, M.S. (2006). Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin. Infect. Dis. 42, 126-131.
30. Sapra, P., and Shor, B. (2013). Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol. Ther. 138, 452-469.
31. Schenone, M., Dančík, V., Wagner, B.K., and Clemons, P.A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232-240.
32. Schreiber, S.L. (2011). Organic synthesis toward small-molecule probes and drugs. Proc. Natl. Acad. Sci. USA 108, 6699-6702.
33. Schreiber, S.L., and Nicolaou, K.C. (1994a). Crossing the boundaries. Chem. Biol. 1, 1.
34. Schreiber, S.L., and Nicolaou, K.C. (1994b). A new journal for an expanding field. Chem. Biol. 1, i-ii.
35. Sievers, E.L., and Senter, P.D. (2013). Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29.
36. Silverman, R.B. (2008). From basic science to blockbuster drug: the discovery of Lyrica. Angew. Chem. Int. Ed. Engl. 47, 3500-3504.
37. Sliwoski, G., Kothiwale, S., Meiler, J., and Lowe, E.W., Jr. (2014). Computational methods in drug discovery. Pharmacol. Rev. 66, 334-395.
38. Swinney, D.C., and Anthony, J. (2011). How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519.
39. Taylor, E.C. (2011). From the wings of butterflies: the discovery and synthesis of Alimta. Chem. Int. 33, 4-8.
40. Towle, M.J., Salvato, K.A., Budrow, J., Wels, B.F., Kuznetsov, G., Aalfs, K.K., Welsh, S., Zheng, W., Seletsky, B.M., Palme, M.H., et al. (2001). In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021.
41. 18F labeling of arenes. Angew. Chem. Int. Ed. Engl. 51, 11426-11437.
42. Waldmann, H. (2012). Drug discovery ... the third in the band!. Angew. Chem. Int. Ed. Engl. 51, 6284-6285.
43. Walsh, C.T., and Fischbach, M.A. (2010). Natural products version 2.0: connecting genes to molecules. J. Am. Chem. Soc. 132, 2469-2493.
44. Weeks, A.M., and Chang, M.C.Y. (2011). Constructing de novo biosynthetic pathways for chemical synthesis inside living cells. Biochemistry 50, 5404-5418.
45. Wetzel, S., Bon, R.S., Kumar, K., and Waldmann, H. (2011). Biology-oriented synthesis. Angew. Chem. Int. Ed. Engl. 50, 10800-10826.
46. Williams, S.A., Anderson, W.C., Santaguida, M.T., and Dylla, S.J. (2013). Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab. Invest. 93, 970-982.
47. Yu, M.J., Kishi, Y., and Littlefield, B.A. (2005). Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In Anticancer Agents from Natural Products, G.M. Cragg, D.G.I. Kingston, and D.J. Newman, eds. (Boca Raton, FL: CRC Press), pp. 241-266.